Atish Choudhury, Md

This study is testing a two-drug combination (relugolix and darolutamide) for men with hormone-sensitive prostate cancer. The main goal is to see if men's testosterone levels return to normal within 18 months after finishing the two-year treatment. Researchers will also closely m…